- Home
- KALV vs MUX Comparison
KALV vs MUX Comparison
Compare KALV & MUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- MUX
- Stock Information
- Founded
- KALV N/A
- MUX 1979
- Country
- KALV United States
- MUX Canada
- Employees
- KALV N/A
- MUX N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- MUX Precious Metals
- Sector
- KALV Health Care
- MUX Basic Materials
- Exchange
- KALV Nasdaq
- MUX Nasdaq
- Market Cap
- KALV 362.2M
- MUX 411.8M
- IPO Year
- KALV N/A
- MUX N/A
- Fundamental
- Price
- KALV $8.75
- MUX $8.34
- Analyst Decision
- KALV Strong Buy
- MUX Strong Buy
- Analyst Count
- KALV 7
- MUX 2
- Target Price
- KALV $27.00
- MUX $15.63
- AVG Volume (30 Days)
- KALV 319.9K
- MUX 399.5K
- Earning Date
- KALV 03-10-2025
- MUX 02-28-2025
- Dividend Yield
- KALV N/A
- MUX N/A
- EPS Growth
- KALV N/A
- MUX N/A
- EPS
- KALV N/A
- MUX 2.07
- Revenue
- KALV N/A
- MUX $199,634,000.00
- Revenue This Year
- KALV N/A
- MUX $22.76
- Revenue Next Year
- KALV N/A
- MUX $18.67
- P/E Ratio
- KALV N/A
- MUX $4.03
- Revenue Growth
- KALV N/A
- MUX 47.02
- 52 Week Low
- KALV $7.30
- MUX $5.92
- 52 Week High
- KALV $16.88
- MUX $12.50
- Technical
- Relative Strength Index (RSI)
- KALV 51.87
- MUX 50.93
- Support Level
- KALV $7.30
- MUX $8.08
- Resistance Level
- KALV $9.16
- MUX $8.60
- Average True Range (ATR)
- KALV 0.41
- MUX 0.32
- MACD
- KALV 0.07
- MUX 0.06
- Stochastic Oscillator
- KALV 78.17
- MUX 75.23
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About MUX McEwen Mining Inc.
McEwen Mining Inc is a mining and minerals production and exploration company focused on precious and base minerals in Argentina, Mexico, and the United States. The company's overall revenue is principally derived from the production of gold and silver. The company owns and operates the wholly-owned El Gallo 1 mine in Mexico, and has a minority shareholding in the company that operates the San Jose mine in Argentina. More than half the company's gold output is produced by the El Gallo 1 mine. The remaining gold production, and the majority of silver production, is produced by the San Jose mine. Geographically, the majority is from Canada.